Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (267)	1/19/1999 1:49:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 579

SIBIA Neurosciences Announces Granting of Key Foreign Patents for Technology Involved in its Recent Successful Litigation Against Cadus Pharmaceuticals, Inc. biz.yahoo.com Dr. William T. Comer, President and CEO at SIBIA Neurosciences stated, ''Having successfully validated our patent rights to the jury in our litigation with Cadus Pharmaceuticals, Inc. in U.S. District Court, we are delighted that the Canadian and European Patent Offices have also recognized the novelty of our pioneering invention. We believe that this technology is being used by a number of biotechnology and pharmaceutical companies and are presently reviewing our licensing strategies for this technology.''

To: scaram(o)uche who wrote (267)	2/1/1999 7:02:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 579

Here's the claim....... That which is claimed is: 1. A method for identifying compounds that modulate cell surface protein-mediated activity by detecting intracellular transduction of a signal generated upon interaction of the compound with the cell surface protein, comprising: comparing the amount of transcription of a reporter gene or the amount of reporter gene product expressed in a first recombinant cell in the presence of the compound with the amount of transcription or product in the absence of the compound, or with the amount of transcription or product in a second recombinant cell; and selecting compounds that change the amount of transcription of a reporter gene or the amount of reporter gene product expressed in the first recombinant cell in the presence of the compound compared to the amount of transcription or product in the absence of the compound, or compared to the amount of transcription or product in the second recombinant cell, wherein: the cell surface protein is a surface receptor or ion channel; the first recombinant cell contains a reporter gene Construct and expresses the cell surface protein; the second recombinant cell is identical to the first recombinant cell, except that it does not express the cell surface protein; and the reporter gene constructs contains: (a) a transcriptional control element that is responsive to the intracellular signal that is generated by the interaction of an agonist with the cell surface protein; and (b) a reporter gene that encodes a detectable transcriptional or translational product and that is in operative association with the transcriptional control element.